Printer Friendly

Laserscope Launches Web Site: www.laserscope.com.

SAN JOSE, Calif.--(BW HealthWire)--Sept. 17, 1997--Laserscope (NASDAQ:LSCP) today announced that it has launched a Web Site designed for customers, physicians, medical consumers, and the general public.

The site can be accessed via the World Wide Web address: www.laserscope.com

Background information on the company, recent press announcements, SEC filings, product descriptions and photos are included in the site, as well as special sections for physicians and medical equipment planners.

Three sections are devoted to consumer information, including useful information on leg and facial vein treatment, wrinkle removal, and treatment of chronic bladder syndrome, a urological condition that some estimates say could affect more than 5 million women in the U.S. annually.

The site can also be accessed through searches on such topics as leg vein treatment, urethral syndrome, wrinkle removal, chronic bladder syndrome, esophageal cancer, new cancer treatment, and others.

"The Laserscope Web Site is another vehicle in our overall effort to further strengthen our relationship with our customers as well as communicate more effectively about our business," said Robert V. McCormick, Laserscope President and CEO. "We also expect the consumer-oriented sections to benefit those seeking timely information on surgical and cosmetic laser treatments."

Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center and hospital markets. In addition, Laserscope's Ascent Medical Systems(TM) (AMS) provide innovative, custom equipment solutions for surgical suites and medical treatment rooms.

Statements in this announcement about future results are preliminary and based on partial information and assumptions. Except for the historical information presented, the matters discussed in this announcement contain forward-looking statements that involve risks and uncertainties, including the timely introduction and market acceptance of new products and procedures such as those described herein, the development and rate of growth of new markets and treatments, the impact of competitive products and technologies, consumer acceptance of and demand for the medical procedures targeted by the company, and other risks detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of the most recent Forms 10K and 10Q are available upon request from Laserscope's Investor Relations Department.

CONTACT: Laserscope, San Jose

Richard Wood (IR/Media), 408/943-0636

Dennis LaLumandiere (Financial), 408/943-0636

or

Hilary Kaye Associates

Hilary Kaye or Shelle Murach, 714/851-5150
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 17, 1997
Words:401
Previous Article:ComStream Links Up With NPR Satellite Services; NPR To Distribute ComStream Satellite Broadcast Products.
Next Article:NeTpower Teams With Microsoft to Bring Internet Explorer 4.0 to Windows NT Workstation Market; Originator of Windows NT Workstation and Server...
Topics:


Related Articles
FDA Gives Marketing Clearance to Innovative Laser-Drug Cancer Treatment; Laserscope to Market Lasers and Devices for New QLT/Sanofi Winthrop...
Laserscope reports first quarter results; company reports net income of 2 cents per share.
Gene Gargiulo Upgrades Laserscope to Buy Rating.
Laserscope and QLT PhotoTherapeutics Extend Their Strategic Alliance.
Laserscope Receives FDA "Approvable Letter" For Use of PDT Laser Systems to Treat Lung Cancer.
Laserscope Announces Strategic Alliance with Celebration Health; State-of-the-Art Hospital is Centerpiece of New Walt Disney-Inspired Community.
Laserscope's PDT Laser Systems Included in Phase I Clinical Trial for Treatment of Atherosclerosis.
Laserscope Receives FDA Clearance for Laser Treatment of BPH.
DAILY NEWS STOCK PICKING CONTEST.
Novecta.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters